Follow
'The heart-focused company says that its ALS candidate, reldesemtiv, was ineffective in a phase 3 trial compared to placebo after a second interim analysis, according to an announcement Friday. The data monitoring committee recommended that the trial be discontinued and Cytokinetics says it will stop treating people with the drug, including patients in the open-label extension. '
